Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts VRDN Hot Sheet
Join SI Premium – FREE
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q2 EPS of ($1.05), $0.02 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $280 thousand versus the consensus estimate of $28 thousand.
For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hillman Solutions (HLMN) Tops Q3 EPS by 1c; Offers Guidance
- Vitesse Energy, Inc. (VTS) Misses Q3 EPS by 129c
- ONE Gas (OGS) Tops Q3 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
